| Nov 4 |
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
|
| Oct 15 |
NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology
|
| Oct 14 |
NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy
|
| Oct 8 |
NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
|
| Sep 26 |
NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs
|
| Aug 26 |
MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX
|
| Aug 19 |
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -
A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
|
| Aug 2 |
Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?
|
| Aug 1 |
"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides
|
| Jul 31 |
NNVC: NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift in Viral Therapy
|
